Artia Global Partners LP Purchases New Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Artia Global Partners LP bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 100,000 shares of the company's stock, valued at approximately $1,917,000. Viridian Therapeutics makes up approximately 0.7% of Artia Global Partners LP's investment portfolio, making the stock its 22nd largest holding. Artia Global Partners LP owned about 0.13% of Viridian Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of VRDN. Loomis Sayles & Co. L P bought a new stake in Viridian Therapeutics in the 4th quarter worth about $26,845,000. Price T Rowe Associates Inc. MD grew its stake in shares of Viridian Therapeutics by 2,847.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company's stock worth $25,436,000 after acquiring an additional 1,281,799 shares during the period. FMR LLC lifted its position in Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock valued at $227,776,000 after purchasing an additional 698,434 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in Viridian Therapeutics by 38.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,670,000 shares of the company's stock worth $32,014,000 after purchasing an additional 465,000 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Viridian Therapeutics during the 4th quarter valued at $7,868,000.

Viridian Therapeutics Price Performance

Shares of VRDN traded up $0.20 during mid-day trading on Friday, reaching $13.94. The stock had a trading volume of 722,193 shares, compared to its average volume of 1,193,855. The business has a fifty day moving average of $14.01 and a 200 day moving average of $18.01. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -3.23 and a beta of 0.81. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.05 million. Equities analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on VRDN. HC Wainwright reiterated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Needham & Company LLC reaffirmed a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.